WM-S1 / WMBIO - LARVOL DELTA

Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy. (PubMed, Cell Death Differ) - "Here, we identified that presence of activated RON could be a possible factor for the development of resistance against anti-EGFR (cetuximab) therapy in colorectal cancer patient tissues. In terms of the immunotherapy, WM-S1-030 elicited notable antitumor immunity in anti-PD-1 resistant cell derived mouse model, likely via repression of M1/M2 polarization of macrophages. These findings suggest that WM-S1-030 could be developed as a new treatment option for cancer patients expressing these three RON variants."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CTNNB1 • KRAS • MST1R

WM-S1, the novel small molecule inhibitor of mutant RTK/receptor tyrosine kinase, for the treatment of cancer (AACR 2022) - "In conclusion, mtRTK is a potential oncogenic driver mutation in various solid tumor. A first-in-class anticancer agent WM-S1 targeting mtRTK can be promising therapeutic agents for cetuximab-resistant colon cancer patients regardless of KRAS mutation status and other cancers."

IO biomarker • Biliary Cancer • Cholangiocarcinoma • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: Wellmarker Bio; Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=100; Not yet recruiting; Sponsor: Wellmarker Bio

Clinical • New P1 trial • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration (PRNewswire) - "Wellmarker Bio...announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer....Under the approval, Wellmarker Bio will seek to recruit a total of 100 advanced cancer patients in multiple centers, including sites in Australia such as the Linear Clinical Center and Monash Hospital, to conduct clinical trials in two stages: Phase Ia (dose escalation) and Phase Ib (dose expansion)."

Non-US regulatory • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Wellmarker Bio introduces Medidata solution to global clinical trials for anticancer drugs [Google translation] (docdocdoc.co.kr) - "Wellmarker Bio announced...that it has introduced Medidata's solution for a global phase 1 clinical trial of 'WM-S1', a candidate for colorectal cancer treatment. The two solutions introduced are 'Rave Study Feasibility'...and 'Rave EDC', an integrated data solution...Wellmarker Bio said that it is planning clinical trials in Korea, Australia, and the United States, and has successfully selected an Australian clinical trial agency through 'Rave Steady Fisibility'."

Licensing / partnership • Colorectal Cancer • Gastrointestinal Cancer • Oncology